$10.50
-0.42-3.85%
At close: -
$11.04
0.545.14%
After Hours: Nov 7, 9:30 AM EDT
Comments
Loading...
4D Molecular Therapeutics Analyst Ratings and Price Targets | NASDAQ:FDMT | Benzinga
4D Molecular Therapeutics Inc has a consensus price target of $31.43 based on the ratings of 15 analysts. The high is $58 issued by Jefferies on April 1, 2024. The low is $6 issued by Morgan Stanley on January 13, 2025. The 3 most-recent analyst ratings were released by RBC Capital, Roth Capital, and Chardan Capital on October 21, 2025, August 12, 2025, and August 12, 2025, respectively. With an average price target of $29.67 between RBC Capital, Roth Capital, and Chardan Capital, there's an implied 168.72% upside for 4D Molecular Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
Roth Capital
Chardan Capital
Goldman Sachs
Barclays
1calculated from analyst ratings
Analyst Ratings for 4D Molecular Therapeutics
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/21/2025 | 135.51% | RBC Capital | $26 → $26 | Reiterates | Outperform → Outperform | |||
08/12/2025 | 244.2% | Roth Capital | $44 → $38 | Maintains | Buy | |||
08/12/2025 | 126.45% | Chardan Capital | $25 → $25 | Maintains | Buy | |||
08/01/2025 | 126.45% | Chardan Capital | $25 → $25 | Maintains | Buy | |||
07/03/2025 | 126.45% | Chardan Capital | $25 → $25 | Maintains | Buy | |||
05/09/2025 | 126.45% | Chardan Capital | $28 → $25 | Maintains | Buy | |||
05/09/2025 | 298.55% | Goldman Sachs | $51 → $44 | Maintains | Buy | |||
05/09/2025 | 244.2% | Barclays | $45 → $38 | Maintains | Overweight | |||
03/10/2025 | 262.32% | B of A Securities | $42 → $40 | Maintains | Buy | |||
03/04/2025 | 153.62% | Chardan Capital | $30 → $28 | Maintains | Buy | |||
03/03/2025 | 217.03% | RBC Capital | $39 → $35 | Maintains | Outperform | |||
03/03/2025 | 226.09% | HC Wainwright & Co. | $36 → $36 | Reiterates | Buy → Buy | |||
02/11/2025 | 171.74% | Chardan Capital | $39 → $30 | Maintains | Buy | |||
02/10/2025 | 226.09% | HC Wainwright & Co. | $36 → $36 | Reiterates | Buy → Buy | |||
01/13/2025 | -45.65% | Morgan Stanley | $8 → $6 | Maintains | Underweight | |||
01/13/2025 | 144.57% | Leerink Partners | $31 → $27 | Maintains | Outperform | |||
01/13/2025 | 226.09% | HC Wainwright & Co. | $36 → $36 | Reiterates | Buy → Buy | |||
12/18/2024 | 316.67% | B of A Securities | $79 → $46 | Maintains | Buy | |||
11/21/2024 | -27.54% | Morgan Stanley | → $8 | Initiates | → Underweight | |||
11/14/2024 | 253.26% | Chardan Capital | $39 → $39 | Maintains | Buy | |||
11/14/2024 | 226.09% | HC Wainwright & Co. | $36 → $36 | Reiterates | Buy → Buy | |||
11/14/2024 | 253.26% | RBC Capital | $40 → $39 | Maintains | Outperform | |||
09/23/2024 | — | Cantor Fitzgerald | — | Downgrade | Overweight → Neutral | |||
09/19/2024 | 253.26% | Chardan Capital | $38 → $39 | Maintains | Buy | |||
09/19/2024 | 226.09% | Leerink Partners | $40 → $36 | Reiterates | Outperform → Outperform | |||
09/19/2024 | 226.09% | HC Wainwright & Co. | $36 → $36 | Reiterates | Buy → Buy | |||
09/09/2024 | — | Cantor Fitzgerald | — | Reiterates | → Overweight | |||
08/09/2024 | 226.09% | HC Wainwright & Co. | $36 → $36 | Reiterates | Buy → Buy | |||
07/22/2024 | 262.32% | RBC Capital | $40 → $40 | Reiterates | Outperform → Outperform | |||
07/18/2024 | 262.32% | BMO Capital | $63 → $40 | Maintains | Outperform | |||
07/17/2024 | 244.2% | Chardan Capital | $38 → $38 | Maintains | Buy | |||
06/26/2024 | 262.32% | RBC Capital | $40 → $40 | Reiterates | Outperform → Outperform | |||
06/07/2024 | 226.09% | HC Wainwright & Co. | $36 → $36 | Reiterates | Buy → Buy | |||
05/13/2024 | 226.09% | HC Wainwright & Co. | $36 → $36 | Reiterates | Buy → Buy | |||
04/15/2024 | 262.32% | RBC Capital | $35 → $40 | Maintains | Outperform | |||
04/15/2024 | 307.61% | Barclays | → $45 | Initiates | → Overweight | |||
04/01/2024 | 470.65% | BMO Capital | $70 → $63 | Maintains | Outperform | |||
04/01/2024 | 425.36% | Jefferies | $30 → $58 | Maintains | Buy | |||
03/01/2024 | 226.09% | HC Wainwright & Co. | $36 → $36 | Reiterates | Buy → Buy | |||
02/07/2024 | 633.7% | Goldman Sachs | → $81 | Reinstates | → Buy | |||
02/05/2024 | 534.06% | BMO Capital | $50 → $70 | Maintains | Outperform | |||
02/05/2024 | 217.03% | RBC Capital | $25 → $35 | Maintains | Outperform | |||
01/29/2024 | 126.45% | RBC Capital | → $25 | Reiterates | Outperform → Outperform | |||
10/24/2023 | 189.86% | Cantor Fitzgerald | → $32 | Initiates | → Overweight | |||
08/11/2023 | 180.8% | Chardan Capital | → $31 | Reiterates | Buy → Buy | |||
08/10/2023 | 226.09% | HC Wainwright & Co. | → $36 | Reiterates | Buy → Buy | |||
07/31/2023 | 226.09% | HC Wainwright & Co. | → $36 | Reiterates | Buy → Buy | |||
07/11/2023 | 180.8% | Chardan Capital | $30 → $31 | Maintains | Buy | |||
07/05/2023 | 171.74% | Chardan Capital | → $30 | Initiates | → Buy | |||
06/08/2023 | 198.91% | B of A Securities | $28 → $33 | Maintains | Buy | |||
06/08/2023 | 226.09% | HC Wainwright & Co. | → $36 | Reiterates | Buy → Buy | |||
05/11/2023 | 226.09% | HC Wainwright & Co. | → $36 | Reiterates | Buy → Buy | |||
04/28/2023 | 226.09% | HC Wainwright & Co. | → $36 | Reiterates | → Buy | |||
04/13/2023 | 17.75% | SVB Securities | $14 → $13 | Maintains | Market Perform | |||
03/16/2023 | 226.09% | HC Wainwright & Co. | → $36 | Reiterates | → Buy | |||
02/23/2023 | 226.09% | HC Wainwright & Co. | → $36 | Reiterates | → Buy | |||
02/06/2023 | 226.09% | HC Wainwright & Co. | → $36 | Reiterates | → Buy | |||
02/06/2023 | 26.81% | SVB Leerink | $15 → $14 | Maintains | Market Perform | |||
01/30/2023 | 352.9% | BMO Capital | → $50 | Initiates | → Outperform | |||
11/18/2022 | 226.09% | HC Wainwright & Co. | → $36 | Initiates | → Buy | |||
11/15/2022 | 515.94% | Goldman Sachs | → $68 | Upgrade | Neutral → Buy | |||
11/14/2022 | 35.87% | SVB Leerink | $11 → $15 | Maintains | Market Perform | |||
11/10/2022 | -0.36% | SVB Leerink | $10 → $11 | Maintains | Market Perform |
FAQ
What is the target price for 4D Molecular Therapeutics (FDMT) stock?
The latest price target for 4D Molecular Therapeutics (NASDAQ:FDMT) was reported by RBC Capital on October 21, 2025. The analyst firm set a price target for $26.00 expecting FDMT to rise to within 12 months (a possible 135.51% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for 4D Molecular Therapeutics (FDMT)?
The latest analyst rating for 4D Molecular Therapeutics (NASDAQ:FDMT) was provided by RBC Capital, and 4D Molecular Therapeutics reiterated their outperform rating.
When was the last upgrade for 4D Molecular Therapeutics (FDMT)?
The last upgrade for 4D Molecular Therapeutics Inc happened on November 15, 2022 when Goldman Sachs raised their price target to $68. Goldman Sachs previously had a neutral for 4D Molecular Therapeutics Inc.
When was the last downgrade for 4D Molecular Therapeutics (FDMT)?
The last downgrade for 4D Molecular Therapeutics Inc happened on September 23, 2024 when Cantor Fitzgerald changed their price target from N/A to N/A for 4D Molecular Therapeutics Inc.
When is the next analyst rating going to be posted or updated for 4D Molecular Therapeutics (FDMT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of 4D Molecular Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for 4D Molecular Therapeutics was filed on October 21, 2025 so you should expect the next rating to be made available sometime around October 21, 2026.
Is the Analyst Rating 4D Molecular Therapeutics (FDMT) correct?
While ratings are subjective and will change, the latest 4D Molecular Therapeutics (FDMT) rating was a reiterated with a price target of $26.00 to $26.00. The current price 4D Molecular Therapeutics (FDMT) is trading at is $11.04, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
